Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome
Abstract Background More than 95% of individuals with RTT have mutations in methyl-CpG-binding protein 2 (MECP2), whose protein product modulates gene transcription. The disorder is caused by mutations in a single gene and the disease severity in affected individuals can be quite variable. Specific...
Main Authors: | Carla Caffarelli, Stefano Gonnelli, Maria Dea Tomai Pitinca, Silvia Camarri, Antonella Al Refaie, Joussef Hayek, Ranuccio Nuti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | BMC Medical Genetics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12881-020-0960-2 |
Similar Items
-
Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice
by: Laura Dean Heckman, et al.
Published: (2014-06-01) -
Mutation analysis of the MECP2 gene in Romanian females with Rett syndrome
by: Dumitriu Simona, et al.
Published: (2013-12-01) -
MeCP2_e2 partially compensates for lack of MeCP2_e1: A male case of Rett syndrome
by: Ryo Takeguchi, et al.
Published: (2020-02-01) -
The Molecular Functions of MeCP2 in Rett Syndrome Pathology
by: Osman Sharifi, et al.
Published: (2021-04-01) -
MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome
by: Xu-Rui Jin, et al.
Published: (2017-10-01)